SCHEMBL4868234

SCHEMBL4868234

NC(=O)C(O)=C(O)c1cc(O)c(O)c(C(=O)NCC=CC2OC(n3cnc4c(N)ncnc43)C(O)C2O)c1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AHCY P23526 13/20 0.51
HIF1A Q16665 1/20 0.47
TMEM97 Q5BJF2 1/20 0.47
SIGMAR1 Q99720 1/20 0.47
ADORA2A P29274 2/20 0.46
HSP90B1 P14625 2/20 0.46
ADORA3 P0DMS8 1/20 0.46
HSP90AA1 P07900 1/20 0.46
PRMT5 O14744 1/20 0.46
PRMT3 O60678 1/20 0.46
PRMT9 Q6P2P2 1/20 0.46
CARM1 Q86X55 1/20 0.46
PRMT6 Q96LA8 1/20 0.46
PRMT1 Q99873 1/20 0.46
PRMT8 Q9NR22 1/20 0.46
PRMT7 Q9NVM4 1/20 0.46
ADORA2B P29275 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4869572 0.90 AHCY (0.51) AHCYADORA2AHSP90B1ADORA3HSP90AA1
SCHEMBL4865596 0.88 AHCY (0.51) AHCYHIF1ATMEM97SIGMAR1ADORA2A
SCHEMBL8285526 0.88 AHCY (0.51) AHCYHIF1ATMEM97SIGMAR1ADORA2A
SCHEMBL14279857 0.88 AHCY (0.51) AHCYADORA2AHSP90B1ADORA3HSP90AA1
SCHEMBL14279835 0.88 AHCY (0.51) AHCYHIF1ATMEM97SIGMAR1ADORA2A
SCHEMBL4867938 0.88 AHCY (0.51) AHCYADORA2AHSP90B1ADORA3HSP90AA1
SCHEMBL4867945 0.88 AHCY (0.51) AHCYADORA2AHSP90B1ADORA3HSP90AA1
SCHEMBL4867397 0.88 AHCY (0.51) AHCYADORA2AHSP90B1ADORA3HSP90AA1
SCHEMBL4868847 0.88 AHCY (0.51) AHCYHIF1ATMEM97SIGMAR1ADORA2A
SCHEMBL4868820 0.88 AHCY (0.51) AHCYHIF1ATMEM97SIGMAR1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
US-20050137162-A1 New COMT inhibitors for the treatment of depression and impaired cognition F. HOFFMANN-LA ROCHE AG (CH) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137162-A1 New COMT inhibitors for the treatment of depression and impaired cognition COMT, MAOB, TPH1 AHCY 814/4885HIF1A 1034/4885TMEM97 3229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.